nach oben

Die Diabetologie

Erschienen in:

21.02.2023 | Typ-2-Diabetes | Leitthema

Therapieoptionen bei diabetischer Nephropathie

verfasst von: Dr. med. R. Morgenroth, Peter R. Mertens, C. Herzog, Florian G. Scurt

Erschienen in: Die Diabetologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die diabetische Nephropathie stellt eine schwerwiegende Komplikation des Diabetes mellitus dar, welche durch metabolische und hämodynamische Veränderungen verursacht wird.

Die sowohl supportiven als auch medikamentösen Therapien beschränkten sich bisher auf die Behandlung kardiovaskulärer Risikofaktoren und die Blockade des Renin-Angiotensin-Aldosteron-Systems. Mit der Entwicklung der SGLT-2-Inhibitoren (SGLT-2: „sodium glucose linked transporter 2“ bzw. Natrium-Glukose-Kotransporter 2) und nichtsteroidalen Mineralokortikoidrezeptorblockern stehen nach jahrelangem Stillstand 2 Medikamentenklassen zur Verfügung, die den proinflammatorischen und profibrotischen Charakter der diabetischen Nephropathie unterdrücken. Darüber hinaus erweitern GLP-1-Rezeptor-Agonisten (GLP-1: „glucagon-like peptide 1“ bzw. glukagonähnliches Peptid 1) womöglich bald das Therapieportfolio. Atrasentan, Selonsertib und Stimulatoren und Aktivatoren der löslichen Guanylatzyklase präsentieren sich als vielversprechende zukünftige Therapieoptionen.

Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS et al (2016) Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316(6):602–610. https://doi.org/10.1001/jama.2016.10924CrossRefPubMedPubMedCentral

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4):S1–S115. https://doi.org/10.1016/j.kint.2020.06.019CrossRef

Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P et al (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 102(2):248–260. https://doi.org/10.1016/j.kint.2022.05.012CrossRefPubMed

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. https://doi.org/10.2337/dci22-0027CrossRefPubMedPubMedCentral

Wanner C, Tonelli M (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85(6):1303–1309. https://doi.org/10.1038/ki.2014.31CrossRefPubMed

Herrera-Gómez F, Chimeno MM, Martín-García D, Lizaraso-Soto F, Maurtua-Briseño-Meiggs Á, Grande-Villoria J et al (2019) Cholesterol-lowering treatment in chronic kidney disease: multistage pairwise and network meta-analyses. Sci Rep 9(1):8951. https://doi.org/10.1038/s41598-019-45431-5CrossRefPubMedPubMedCentral

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 73(24):3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002CrossRefPubMed

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR et al (2019) Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 380(11):1022–1032. https://doi.org/10.1056/NEJMoa1803917CrossRefPubMed

Leiter LA, Banach M, Catapano AL, Duell PB, Gotto AM Jr., Laufs U et al (2022) Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab 24(5):868–880. https://doi.org/10.1111/dom.14645CrossRefPubMedPubMedCentral

10.

Ray KK, Wright S, Kallend D, Koenig W, Leiter L, Raal F et al (2020) Inclisiran and cardiovascular outcomes: analyses from orion-11. J Am Coll Cardiol 75(11):238. https://doi.org/10.1016/S0735-1097(20)30865-2CrossRef

11.

Wright RS, Kallend D, Ray KK, Leiter L, Koenig W, Raal F et al (2020) Evaluation of LDL‑C reductions BY Sirna treatment with Inclisiran IN patients with diabetes mellitus, metabolic syndrome or neither. J Am Coll Cardiol 75(11):2005. https://doi.org/10.1016/S0735-1097(20)32632-2CrossRef

12.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860. https://doi.org/10.1056/NEJMoa011303CrossRefPubMed

13.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001) Effects of iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869. https://doi.org/10.1056/NEJMoa011161CrossRefPubMed

14.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):S1–S87. https://doi.org/10.1016/j.kint.2020.11.003CrossRef

15.

Busch M, Mann J, Wolf G (2021) KDIGO-Leitlinie zur Behandlung des Diabetes mellitus bei chronischer Nierenerkrankung. Nephrologe 16(3):169–176. https://doi.org/10.1007/s11560-021-00498-yCrossRef

16.

Palmer BF, Clegg DJ (2022) Kidney-protective effects of SGLT2 inhibitors. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.09380822CrossRefPubMedPubMedCentral

17.

DeFronzo RA, Reeves WB, Awad AS (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 17(5):319–334. https://doi.org/10.1038/s41581-021-00393-8CrossRefPubMed

18.

van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL et al (2020) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97(1):202–212. https://doi.org/10.1016/j.kint.2019.09.013CrossRefPubMed

19.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720CrossRefPubMed

20.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389CrossRefPubMed

21.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F‑F et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816CrossRefPubMed

22.

EMPA-KIDNEY Collaborative Group et al (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233CrossRef

23.

Braunwald E (2022) Gliflozins in the management of cardiovascular disease. N Engl J Med 386(21):2024–2034. https://doi.org/10.1056/NEJMra2115011CrossRefPubMed

24.

American Diabetes Association (2022) Standards of medical care in diabetes—2022 abridged for primary care providers. Clin Diabetes 40(1):10–38. https://doi.org/10.2337/cd22-as01CrossRefPubMedCentral

25.

Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosma S (2019) GLP‑1 receptor agonists and kidney protection. Medicina. https://doi.org/10.3390/medicina55060233CrossRefPubMedPubMedCentral

26.

Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ et al (2017) GLP‑1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13(10):605–628. https://doi.org/10.1038/nrneph.2017.123CrossRefPubMed

27.

Tommerdahl KL, Kendrick J, Bjornstad P (2022) The role of glucagon-like peptide 1 (GLP-1) receptor agonists in the prevention and treatment of diabetic kidney disease: insights from the AMPLITUDE‑O trial. Clin J Am Soc Nephrol 17(6):905–907. https://doi.org/10.2215/CJN.00020122CrossRefPubMed

28.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141CrossRefPubMed

29.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/NEJMoa1603827CrossRefPubMedPubMedCentral

30.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3CrossRefPubMed

31.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S et al (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377(9):839–848. https://doi.org/10.1056/NEJMoa1616011CrossRefPubMed

32.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394(10193):131–138. https://doi.org/10.1016/s0140-6736(19)31150-xCrossRefPubMed

33.

Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z et al (2022) Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS‑4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10(11):774–785. https://doi.org/10.1016/S2213-8587(22)00243-1CrossRefPubMed

34.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141CrossRefPubMed

35.

Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(8):605–617. https://doi.org/10.1016/S2213-8587(18)30104-9CrossRefPubMed

36.

Barrera-Chimal J, André-Grégoire G, Nguyen Dinh Cat A, Lechner SM, Cau J, Prince S et al (2017) Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol 28(4):1216–1226. https://doi.org/10.1681/asn.2016040477CrossRefPubMedPubMedCentral

37.

Barrera-Chimal J, Estrela GR, Lechner SM, Giraud S, El Moghrabi S, Kaaki S et al (2018) The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin‑4 receptor signaling. Kidney Int 93(6):1344–1355. https://doi.org/10.1016/j.kint.2017.12.016CrossRefPubMed

38.

Butler MJ, Ramnath R, Kadoya H, Desposito D, Riquier-Brison A, Ferguson JK et al (2019) Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx. Kidney Int 95(1):94–107. https://doi.org/10.1016/j.kint.2018.08.024CrossRefPubMed

39.

Jo R, Shibata H, Kurihara I, Yokota K, Kobayashi S, Murai-Takeda A et al (2022) Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O‑GlcNAc modification. Hypertens Res. https://doi.org/10.1038/s41440-022-01036-6CrossRefPubMed

40.

Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E et al (2004) Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66(4):1493–1502. https://doi.org/10.1111/j.1523-1755.2004.00913.xCrossRefPubMed

41.

Han S‑Y, Kim C‑H, Kim H‑S, Jee Y‑H, Song H‑K, Lee M‑H et al (2006) Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17(5):1362–1372. https://doi.org/10.1681/asn.2005111196CrossRefPubMed

42.

Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S et al (2008) Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 589(1):264–271. https://doi.org/10.1016/j.ejphar.2008.06.019CrossRefPubMed

43.

Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ et al (2014) Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 25(10):2231–2240. https://doi.org/10.1681/asn.2012111094CrossRefPubMedPubMedCentral

44.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L et al (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68(6):2829–2836. https://doi.org/10.1111/j.1523-1755.2005.00756.xCrossRefPubMed

45.

van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D et al (2006) Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 24(11):2285–2292. https://doi.org/10.1097/01.hjh.0000249708.44016.5cCrossRefPubMed

46.

Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T et al (2015) Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol 19(6):1098–1106. https://doi.org/10.1007/s10157-015-1106-2CrossRefPubMedPubMedCentral

47.

Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z et al (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone’s antifibrotic activity. Hypertension 71(4):599–608. https://doi.org/10.1161/hypertensionaha.117.10360CrossRefPubMed

48.

Droebner K, Pavkovic M, Grundmann M, Hartmann E, Goea L, Nordlohne J et al (2021) Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal miralocorticoid receptor antagonist Finerenone in progressive models of kidney fibrosis. Am J Nephrol 52(7):588–601. https://doi.org/10.1159/000518254CrossRefPubMed

49.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845CrossRefPubMed

50.

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2021) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474–484. https://doi.org/10.1093/eurheartj/ehab777CrossRefPubMedCentral

51.

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with Finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252–2263. https://doi.org/10.1056/NEJMoa2110956CrossRefPubMed

52.

Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G et al (2022) A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. https://doi.org/10.1093/ckj/sfac234CrossRefPubMedPubMedCentral

53.

Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM et al (2022) Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter‑2 inhibitor therapy. Kidney Int Rep 7(1):36–45. https://doi.org/10.1016/j.ekir.2021.10.008CrossRefPubMed

54.

Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R et al (2022) Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145(19):1460–1470. https://doi.org/10.1161/CIRCULATIONAHA.121.057736CrossRefPubMed

55.

Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB et al (2022) Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR endpoint study (CONFIDENCE). Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfac198CrossRefPubMedCentral

56.

Ahmad N, Veerapalli H, Lankala CR, Castaneda EE, Aziz A, Rockferry AG et al (2021) Endothelin receptor antagonists as a potential treatment of diabetic nephropathy: a systematic review. Cureus 13(11):e19325. https://doi.org/10.7759/cureus.19325CrossRefPubMedPubMedCentral

57.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF et al (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393(10184):1937–1947. https://doi.org/10.1016/s0140-6736(19)30772-xCrossRefPubMed

58.

Heerspink HJL, de Zeeuw D (2022) Endothelin receptor antagonists for kidney protection: lessons from the SONAR trial. Clin J Am Soc Nephrol 17(6):908–910. https://doi.org/10.2215/cjn.00560122CrossRefPubMed

59.

Badal SS, Al Tuhaifi T, Yu Y‑F, Lopez D, Plato CT, Joly K et al (2022) Selonsertib enhances kidney protection beyond standard of care in a hypertensive, secondary glomerulosclerosis CKD model. Kidney 3(7):1169–1182. https://doi.org/10.34067/kid.0001032022CrossRef

60.

Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD (2019) Effects of selonsertib in patients with diabetic kidney disease. J Am Soc Nephrol 30(10):1980–1990. https://doi.org/10.1681/asn.2018121231CrossRefPubMedPubMedCentral

61.

Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP (2021) Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol 264:355–394. https://doi.org/10.1007/164_2018_197CrossRefPubMed

62.

Maruno S, Tanaka T, Nangaku M (2022) Exploring molecular targets in diabetic kidney disease. Kidney Res Clin Pract 41(2):S33–S45. https://doi.org/10.23876/j.krcp.21.251CrossRefPubMedPubMedCentral

63.

Harloff M, Pruschenk S, Seifert R, Schlossmann J (2022) Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice. Br J Pharmacol 179(11):2460–2475. https://doi.org/10.1111/bph.15425CrossRefPubMed

64.

Czirok S, Fang L, Radovits T, Szabo G, Szenasi G, Rosivall L et al (2017) Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ss expression in type‑1 diabetic rats. Sci Rep 7(1):11218. https://doi.org/10.1038/s41598-017-10125-3CrossRefPubMedPubMedCentral

65.

Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP et al (2020) Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial. Clin J Am Soc Nephrol 16(1):59–69. https://doi.org/10.2215/CJN.08410520CrossRefPubMedPubMedCentral

66.

EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ et al (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233CrossRef

67.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038CrossRefPubMed

68.

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286CrossRefPubMed

Titel: Therapieoptionen bei diabetischer Nephropathie
verfasst von: Dr. med. R. Morgenroth
Peter R. Mertens
C. Herzog
Florian G. Scurt
Publikationsdatum: 21.02.2023
Verlag: Springer Medizin
Schlagwörter: Typ-2-Diabetes
Diabetische Nephropathie
Chronische Nierenerkrankung
Dulaglutid
Diabetes mellitus
Albuminurie
Natrium-Glukose-Kotransporter-2-Hemmer
Erschienen in: Die Diabetologie / Ausgabe 3/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-023-01003-w

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Es ist nicht immer Diabetes mellitus

Histopathologische Veränderungen bei diabetischer Nephropathie

Risiko einer schweren Hypoglykämie bei gleichzeitiger Einnahme von β-Blockern und Sulfonylharnstoffen

Metabolisches Gedächtnis bei diabetischer Nierenerkrankung

Zeitensprung bei der Diagnostik und Behandlung diabetischer Nierenschäden

DDG Praxisempfehlungen: DIfE – Deutscher Diabetes-Risiko-Test®

Praxisempfehlungen der Deutschen Diabetes Gesellschaft